Nykode Therapeutics CEO after another million-dollar deal: We have no competitors

Nykode Therapeutics – formerly Vaccibody – is not up for sale despite the fact that some of the world's biggest biotech businesses are fawning over its technology. CEO Michael Engsig says that they're open to partnerships, even though the company is economically sorted for the future.
Michael Engsig began his career in Norwegian Vaccibody as COO. Today, he has sealed another million.dollar deal as the company's CEO. | Photo: Vaccibody / PR
Michael Engsig began his career in Norwegian Vaccibody as COO. Today, he has sealed another million.dollar deal as the company's CEO. | Photo: Vaccibody / PR
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN

Some of the biggest biotech players in the world are swarming around the Norwegian company Nykode Therapeutics, which was named Vaccibody until yesterday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading